

Grazoprevir PK Fact Sheet


Produced July 2022

Page 1 of 2

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

Details

Generic Name	Grazoprevir
Trade Name	Zepatier® (co-formulated with elbasvir)
Class	HCV NS3/4A protease inhibitor
Molecular Weight	766.90
Structure	



Summary of Key Pharmacokinetic Parameters

Grazoprevir is available in a fixed-dose combination product with elbasvir.

Linearity/non-linearity	Grazoprevir pharmacokinetics increased in a greater than dose-proportional manner over the range of 10-800 mg once daily in HCV-infected subjects.
Steady state	Achieved after approximately 6 days of once daily dosing.
Plasma half life	~31 h
C _{max}	165 (161, 176) ng/ml (mean, 90% CI, based on population PK modelling)
C ₂₄	18.0 (17.8, 19.9) ng/ml (mean, 90% CI, based on population PK modelling)
AUC	1420 (1400, 1530) ng.h/ml (mean, 90% CI, based on population PK modelling)
Bioavailability	Not determined
Absorption	Relative to fasting conditions, the administration of a single dose of elbasvir/grazoprevir with a high-fat (900 kcal, 500 kcal from fat) meal to healthy subjects increased grazoprevir AUC and C _{max} by approximately 1.5-fold and 2.8-fold, respectively. These differences in exposure are not clinically relevant; therefore, elbasvir/grazoprevir may be taken without regard to food.
Protein Binding	>98.8%
Volume of Distribution	1250 L (based on population PK modelling)
CSF:Plasma ratio	Not determined
Semen:Plasma ratio	Not determined
Renal Clearance	<1%
Renal Impairment	No dosage adjustment of elbasvir/grazoprevir is recommended in patients with any degree of renal impairment including patients on haemodialysis. Grazoprevir is not removed by haemodialysis and is unlikely to be removed by peritoneal dialysis as it is highly protein bound.
Hepatic Impairment	No dosage adjustment of elbasvir/grazoprevir is recommended in patients with mild hepatic impairment (Child-Pugh A). Elbasvir/grazoprevir is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C) due to the expected significantly increased grazoprevir plasma concentration (a 12-fold increase in grazoprevir exposure was observed in non-HCV infected Child-Pugh C subjects) and the increased risk of alanine aminotransferase (ALT) elevations.

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Grazoprevir PK Fact Sheet

Produced July 2022

Page 2 of 2

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

Metabolism and Distribution

<i>Metabolised by</i>	CYP3A
<i>Inducer of</i>	Unlikely to induce CYP1A2, CYP2B6, CYP3A.
<i>Inhibitor of</i>	Inhibits BCRP. Weak inhibitor of CYP3A. Does not inhibit P-gp. No clinically significant inhibition of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6, UGT1A1, and esterases (CES1, CES2, and CatA) expected.
<i>Transported by</i>	OATP1B1/3, P-gp

References

Unless otherwise stated (see below), information is from:

Zepatier® Summary of Product Characteristics, Merck Sharp & Dohme Ltd.

Zepatier® US Prescribing Information, Merck & Co Inc.